A Study to Evaluate Different Oral Formulations of KT-621

Part of paid clinical trials in Lincoln, Nebraska.

Sponsor
Kymera Therapeutics, Inc.
Study ID
NCT07823205
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Healthy Participants

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • KT-621 — DRUG
    KT-621 Reference Oral Formulation
  • KT-621 — DRUG
    KT-621 Test Oral Formulation #1
  • KT-621 — DRUG
    KT-621 Test Oral Formulation #2

Study Details

This is a Phase I study to evaluate the relative bioavailability and safety and tolerability of different oral formulations of KT-621 in healthy adult participants.

Key Dates

First listed
Sep 16, 2026
Start date
Oct 31, 2026
Status verified
Sep 2026
Primary completion
Apr 30, 2027
Completion
May 31, 2027

Study Design

Enrollment
54 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER

Arms

  • Experimental: Part A: KT-621 Test Formulation #1
    Participants will receive KT-621 in different oral formulations in a one-way crossover design.
  • Experimental: Part B: KT-621 Test Formulation #2
    Participants will receive KT-621 in different oral formulations in a one-way crossover design.

Primary Outcome Measure

Maximum Plasma Concentration (Cmax) of KT-621 [ Time Frame: Day 1 through Day 24 (Part A); Day 1 through Day 30 (Part B) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
CelerionLincolnNebraska68502-

Find similar trials in Lincoln, NE

By research site
Celerion· Lincoln, NE

Related Studies